Caisse DE Depot ET Placement DU Quebec increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 1.9% during the third quarter, according to its most recent filing with the SEC. The fund owned 26,902 shares of the medical research company’s stock after buying an additional 500 shares during the quarter. Caisse DE Depot ET Placement DU Quebec’s holdings in Edwards Lifesciences were worth $2,953,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the stock. Envestnet Asset Management Inc. boosted its holdings in shares of Edwards Lifesciences by 21.0% in the 3rd quarter. Envestnet Asset Management Inc. now owns 177,580 shares of the medical research company’s stock worth $19,410,000 after buying an additional 30,803 shares during the last quarter. Bluestein R H & Co. boosted its holdings in shares of Edwards Lifesciences by 36.6% in the 3rd quarter. Bluestein R H & Co. now owns 7,465 shares of the medical research company’s stock worth $816,000 after buying an additional 2,000 shares during the last quarter. Private Advisor Group LLC lifted its holdings in Edwards Lifesciences by 9.5% during the third quarter. Private Advisor Group LLC now owns 6,746 shares of the medical research company’s stock valued at $743,000 after purchasing an additional 583 shares during the last quarter. Stifel Financial Corp lifted its holdings in Edwards Lifesciences by 9.9% during the third quarter. Stifel Financial Corp now owns 51,359 shares of the medical research company’s stock valued at $5,617,000 after purchasing an additional 4,638 shares during the last quarter. Finally, FDO Partners LLC lifted its holdings in Edwards Lifesciences by 69.4% during the third quarter. FDO Partners LLC now owns 13,063 shares of the medical research company’s stock valued at $1,428,000 after purchasing an additional 5,352 shares during the last quarter. 81.82% of the stock is currently owned by institutional investors.

Shares of Edwards Lifesciences Corporation (NYSE:EW) traded up $0.15 on Tuesday, hitting $118.18. The stock had a trading volume of 1,321,500 shares, compared to its average volume of 1,641,517. Edwards Lifesciences Corporation has a 12-month low of $86.55 and a 12-month high of $121.45. The company has a market capitalization of $24,977.50, a PE ratio of 32.69, a PEG ratio of 2.11 and a beta of 0.51. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.76 and a current ratio of 3.49.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.86 by ($0.02). Edwards Lifesciences had a net margin of 22.47% and a return on equity of 27.22%. The company had revenue of $821.50 million for the quarter, compared to the consensus estimate of $833.85 million. During the same quarter in the prior year, the company earned $0.68 earnings per share. The company’s quarterly revenue was up 11.1% on a year-over-year basis. equities analysts expect that Edwards Lifesciences Corporation will post 3.76 earnings per share for the current year.

Edwards Lifesciences declared that its board has authorized a stock buyback program on Thursday, December 7th that authorizes the company to repurchase $1.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to repurchase shares of its stock through open market purchases. Stock repurchase programs are typically an indication that the company’s management believes its shares are undervalued.

Several research firms have commented on EW. Canaccord Genuity reaffirmed a “buy” rating and set a $155.00 price objective on shares of Edwards Lifesciences in a report on Sunday, October 8th. Cowen reaffirmed a “buy” rating and set a $135.00 price objective on shares of Edwards Lifesciences in a report on Thursday, October 12th. Barclays dropped their price objective on shares of Edwards Lifesciences from $120.00 to $118.00 and set an “equal weight” rating on the stock in a report on Wednesday, October 25th. BidaskClub downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Friday, August 25th. Finally, Royal Bank of Canada reaffirmed a “buy” rating and set a $130.00 price objective on shares of Edwards Lifesciences in a report on Friday, September 1st. Six investment analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $126.43.

In related news, Director Schack Wesley W. Von sold 1,000 shares of the company’s stock in a transaction that occurred on Thursday, November 9th. The shares were sold at an average price of $104.15, for a total value of $104,150.00. Following the transaction, the director now directly owns 2,622 shares in the company, valued at $273,081.30. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,300 shares of the company’s stock in a transaction that occurred on Friday, September 29th. The stock was sold at an average price of $108.86, for a total transaction of $576,958.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 139,580 shares of company stock worth $14,849,205. Company insiders own 2.13% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Edwards Lifesciences Corporation (EW) Shares Bought by Caisse DE Depot ET Placement DU Quebec” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another domain, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/12/12/edwards-lifesciences-corporation-ew-shares-bought-by-caisse-de-depot-et-placement-du-quebec.html.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.